Yalçin Ş, Güler N, Kansu E, Ertenli I, Güllü I, Barişta I, Çelik I, Kars A, Tekuzman G, Baltali E, Firat D
a Hacettepe University, Institute of Oncology , Ankara , Turkey.
Hematology. 1996;1(2):155-61. doi: 10.1080/10245332.1996.11746299.
This study was aimed to evaluate the efficacy of G-CSF (Granulocyte colony stimulating factor) administration to 37 patients with neutropenia following intensive combination chemotherapy. The patients were divided into two subgroups including solid tumors given ifosfamide and etoposide combination chemotherapy (IMET subgroup) and acute myeloid leukemia (AML) patients treated with mitoxantrone and cytarabine. Control group consisted of 31 acute myeloid leukemia patients. G-CSF was started on the first day of absolute neutropenia until the absolute neutrophil count was above 1000/mm(3) for two consecutive days. G-CSF was found to be effective for early recovery of neutrophil count. Expected response was achieved within 14 days in 91.5% of the courses with a median of fifth day of G-CSF treatment. In conclusion, this study showed the efficacy of G-CSF in early recovery of neutrophil count without any reduction in the incidence of febrile episodes and documented rates of bacterial and fungal infections in patients with acute myeloid leukemia.
本研究旨在评估给予37例接受强化联合化疗后出现中性粒细胞减少的患者粒细胞集落刺激因子(G-CSF)的疗效。患者被分为两个亚组,包括接受异环磷酰胺和依托泊苷联合化疗的实体瘤患者(IMET亚组)以及接受米托蒽醌和阿糖胞苷治疗的急性髓系白血病(AML)患者。对照组由31例急性髓系白血病患者组成。G-CSF在绝对中性粒细胞减少的第一天开始使用,直至绝对中性粒细胞计数连续两天高于1000/mm³。发现G-CSF对中性粒细胞计数的早期恢复有效。91.5%的疗程在14天内达到预期反应,G-CSF治疗的中位时间为第五天。总之,本研究表明G-CSF在急性髓系白血病患者中性粒细胞计数的早期恢复中有效,且发热事件的发生率、细菌和真菌感染的记录率均无降低。